Factory Supply high quality raw Material Rapamycin CAS 53123-88-9 CAS NO.53123-88-9

Wuhan 90000 Lithium Industry and Trade Co., Ltd is a renowned pharmaceutical manufacturer. We specializing in the production of research and development of pharmaceutical intermediates, this kind of products with high quality price concessions, welcomed the new and old customers advisory purchase, companies invest large fund and brain research fine chemical r&d department,biochemical,  pharmaceutical and intermediate products to meet the demand of the market. High level research team,advanced equipment and good scientific atmosphere ensure the quality .

1.Reasonable and competitive price. Provide the best and professional service.Provide the best and professional service is our purpose.

2. Reliable shipping way.Door to door service, guarantee 100% delivery for you.

We have our own shipping agent in each country,we have special lines to your country, you no need do anything.

Will finish all the customs clearance at our side, customers are without any customs issues,door to door delivery.

3.To below countries, we are very  familiar and regular.

UK,USA,Canada,Russia,Ukraine,Kazakhstan,Belarus,Germany,Poland,Sweden,the Netherlands, Australia,Spain,Mexico,Poland  and so on. All are without problems.

Rapamycin

CAS 53123-88-9

MF: C51H79NO13

MW: 914.17

EINECS: 610-965-5

Melting point 183-185°C

alpha D25 -58.2° (methanol)

Boiling point 799.83°C (rough estimate)

density 1.0352 (rough estimate)

vapor pressure 0.56 hPa ( 20 °C)

refractive index 1.5280 (estimate)

Fp 87 °C

storage temp. -20°C

solubility ethanol: soluble2MM

pka 10.40±0.70(Predicted)

form solution

color colorless to yellow

Uses Rapamycin is a triene macrolide discovered in 1995 as a metabolite of Streptomyces hygroscopicus found in a soil obtained on Rapi Nui (Easter Island). Rapamycin displayed potent and selective antifungal activity, notably against Candida albicans. Interest in the metabolite waned until the structural relationship to the potent immunosuppressant fujimycin (Antibiotic FK506) was recognised in the mid-1980s. This recognition led to the re-discovery of rapamycin as a highly selective antitumour and immunosuppressant. Rapamycin inhibits the activity of the protein, mTOR (mammalian target of rapamycin) which functions in a signalling pathway to promote tumour growth. Rapamycin binds to a receptor protein (FKBP12). The rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signalling pathway.

Uses Rapamycin is a triene macrolide discovered in 1974 as a metabolite of Streptomyces hygroscopicus found in a soil obtained on Rapa Nui (Easter Island). Rapamycin displayed potent and selective antifungal activity, notably against Candida albicans. Interest in the metabolite waned until the structural relationship to the potent immunosuppressant fujimycin (Antibiotic FK506) was recognised in the mid-1980s. This recognition led to the re-discovery of rapamycin as a highly selective antitumor and immunosuppressant. Rapamycin inhibits the activity of the protein, mTOR (mammalian target of rapamycin) which functions in a signalling pathway to promote tumor growth. Rapamycin binds to a receptor protein (FKBP12). The rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signalling pathway.

Uses Labelled Rapamycin. A triene macrolide antibiotic isolated from Streptomyces hygroscopicus. Name derived from the native word for Easter Island, Rapa?Nui. Used as an immunosuppressant; antirestenotic. This compound contains aproximately 2% d0.;Labeled Sir

Uses Rapamycin is an immunosuppressant that is used primarily to prevent the rejection of organ and bone marrow transplant. It was first described as a potent inhibitor of IL-2 activation of lymphocytes (IC50 = 5 pM). It is now known that rapamycin specifically interacts with the cytosolic FK-binding protein 12 (FKBP12) to form a complex which inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding to mTOR Complex 1 (mTORC1). Rapamycin and other inhibitors of mTORC1 signaling show potential in treating cancer, adipogenesis, diabetes, tuberous sclerosis, and cardiovascular disease